Name (Synonyms) | Correlation | |
---|---|---|
drug395 | DAS181 OL Wiki | 0.50 |
drug413 | Delayed diagnostics Anyplex TMII RV16 Detection Wiki | 0.50 |
drug394 | DAS181 COVID-19 Wiki | 0.50 |
drug1129 | Rapid diagnostics using Anyplex TMII RV16 Detection Wiki | 0.50 |
drug1107 | Questionnaire with precaution information Wiki | 0.50 |
drug495 | Experimental: Questionnaire without precaution information Wiki | 0.50 |
drug177 | Biological Sample Collection Wiki | 0.50 |
drug472 | Enoxaparin Wiki | 0.22 |
drug1016 | Placebo Wiki | 0.12 |
Name (Synonyms) | Correlation | |
---|---|---|
D005335 | Fever of Unknown Origin NIH | 0.50 |
D002647 | Chilblains NIH | 0.50 |
D002637 | Chest Pain NIH | 0.50 |
D018184 | Paramyxoviridae Infections NIH | 0.29 |
D004417 | Dyspnea NIH | 0.22 |
D007251 | Influenza, Human NIH | 0.19 |
D012141 | Respiratory Tract Infections NIH | 0.11 |
D003141 | Communicable Diseases NIH | 0.10 |
D007239 | Infection NIH | 0.07 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0100749 | Chest pain HPO | 0.50 |
HP:0002098 | Respiratory distress HPO | 0.22 |
HP:0011947 | Respiratory tract infection HPO | 0.11 |
There are 4 clinical trials
This study will seek to enroll immunocompromised patients with Lower Tract parainfluenza infection. It also contains a sub-study to enroll patients with severe COVID-19.
Description: Removal of all oxygen support (with stable SpO2)
Measure: Percent of subjects who Return to Room Air (RTRA) (main study) Time: by Day 28This is a Phase IIb study consisting of two cohorts to evaluate efficacy, safety and pharmacokinetics of DAS181 in IFV infection. An approximate total of 280 subjects will be enrolled into this study.
Description: Percent of subjects who have returned to room air
Measure: Percent of subjects who have returned to room air Time: 7 daysDescription: Percent change of subjects return to baseline oxygen requirement by Day 7 compared to Day 1
Measure: Percent change of subjects return to baseline oxygen requirement Time: 7 daysThe objective of the study is to investigate the safety and potential efficacy of DAS181 for the treatment of severe COVID-19.
Description: Percent of subjects with improved clinical status
Measure: Improved clinical status Time: Day 14Description: Percent of subjects return to room air
Measure: Return to room air Time: Day 14Description: time to SARS-CoV-2 RNA in the respiratory specimens being undetectable
Measure: SARS-CoV-2 RNA Time: 28 daysDescription: Percent of patients discharge from hospital
Measure: Discharge Time: Days 14, 21, 28Description: All-cause mortality rate
Measure: Death Time: Day 14, 21, 28It is a multicenter, randomized, placebo-controlled, double-blind study. The study population is defined as subjects diagnosed with lower respiratory tract COVID-19 who require supplemental oxygen ≥2 LPM at the time of randomization.
Description: Percent of subjects improved (1 to 6 where higher score means worse outcome)
Measure: COVID-19 Clinical Classification (CCC) Time: Day 14Description: Percent of subjects return to room air (RTRA)
Measure: Return to room air (RTRA) Time: Day 14Description: time to Improved COVID-19 Clinical Classification 1 to 6 (where higher score means worse outcome)
Measure: Improved COVID-19 Clinical Classification Time: Day 28Description: Percent of subjects RTRA
Measure: Return To Room Air (RTRA) Time: Day 10, 21, 28Description: Time to
Measure: Death (all cause) Time: Day 28Description: Time to
Measure: SARS-CoV-2 RNA undetectable Time: Day 28Description: Percent of subjects discharge
Measure: Percent of subjects discharged Time: Day 14, 21, 28Description: Time to
Measure: Clinical Deterioration Time: Day 28